{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:07:17Z","timestamp":1747166837066,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2023.100399","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T18:02:08Z","timestamp":1701108128000},"page":"100399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed\/refractory multiple myeloma: a challenging and happy ending fight"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2295-7321","authenticated-orcid":false,"given":"Claudia","family":"Ielo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lrr.2023.100399_bib0001","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lrr.2023.100399_bib0002","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1097\/HS9.0000000000000691","article-title":"Anti-BCMA CAR T-cell therapy: changing the natural history of multiple myeloma","volume":"6","author":"Puertas","year":"2022","journal-title":"Hemasphere"},{"issue":"10","key":"10.1016\/j.lrr.2023.100399_bib0003","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.lrr.2023.100399_bib0004","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","article-title":"COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP","volume":"6","author":"Busca","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.lrr.2023.100399_bib0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lrr.2023.100399_bib0006","doi-asserted-by":"crossref","first-page":"304.e1","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transplant. Cell Ther."},{"issue":"7","key":"10.1016\/j.lrr.2023.100399_bib0007","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.lrr.2023.100399_bib0008","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jiac.2022.10.012","article-title":"Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma","volume":"29","author":"Zhou","year":"2023","journal-title":"J. Infect. Chemother."},{"issue":"6","key":"10.1016\/j.lrr.2023.100399_bib0009","doi-asserted-by":"crossref","first-page":"398.e1","DOI":"10.1016\/j.jtct.2023.03.005","article-title":"Severe acute respiratory syndrome coronavirus 2 vaccine immunogenicity among chimeric antigen receptor T cell therapy recipients","volume":"29","author":"Aleissa","year":"2023","journal-title":"Transplant. Cell Ther."},{"issue":"23","key":"10.1016\/j.lrr.2023.100399_bib0010","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.lrr.2023.100399_bib0011","series-title":"The EBMT\/EHA CAR-T Cell Handbook","article-title":"Management of hypogammaglobulinemia and B-cell aplasia","author":"Topp","year":"2022"},{"key":"10.1016\/j.lrr.2023.100399_bib0012","article-title":"COVID-19 and other viral infections in patients with hematologic malignancies","volume":"43","author":"Harris","year":"2023"},{"issue":"10","key":"10.1016\/j.lrr.2023.100399_bib0013","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00277-022-04924-6","article-title":"Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies","volume":"101","author":"Magyari","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.lrr.2023.100399_bib0014","article-title":"Clinical management of patients with B-cell depletion agents to treat or prevent prolonged and severe SARS-COV-2 infection: defining a treatment pathway","volume":"13","author":"D'Abramo","year":"2022","journal-title":"Front. Immunol."},{"issue":"23","key":"10.1016\/j.lrr.2023.100399_bib0015","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:10:23Z","timestamp":1718903423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048923000390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":15,"alternative-id":["S2213048923000390"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100399","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed\/refractory multiple myeloma: a challenging and happy ending fight","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100399","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100399"}}